This law, if enacted, would specifically impact the budget for cancer research, allowing the NCI to conduct or support innovative studies and trials. The additional funding is intended not only to accelerate research efforts but also to support the development of new cancer drugs. Furthermore, the law mandates a thorough investigation into current cancer drug shortages, addressing economic factors, supply chain issues, and approval delays with the aim of improving drug availability for patients in need.
Summary
House Bill 6807, also known as the 'Knock Out Cancer Act' or 'KO Cancer Act', aims to increase funding for cancer research by the National Cancer Institute (NCI). The bill proposes to appropriate amounts equal to 25 percent of the total funds allocated to the NCI for the fiscal year 2022 from the Treasury, specifically earmarked for cancer research activities over a five-year period (2024 to 2028). This significant funding boost seeks to address the escalating mortality rates attributed to cancer and enhance research efforts in the field.
Contention
While the bill has gained bipartisan support, there may be points of contention regarding the allocation and management of the increased funds. Concerns may be raised about how effectively the funds are utilized, as well as the timeline for delivering results on the studies mandated by the bill. Moreover, the report to Congress on cancer drug shortages may lead to discussions about pharmacoeconomic strategies and regulation changes that could impact drug pricing and availability in the market.